The role of antenatal immunoprophylaxis in the prevention of maternal-foetal anti-Rh(D) alloimmunisation.
作者信息
Liumbruno Giancarlo Maria, D'Alessandro Angelo, Rea Federica, Piccinini Vanessa, Catalano Liviana, Calizzani Gabriele, Pupella Simonetta, Grazzini Giuliano
机构信息
Centro Nazionale Sangue, Istituto Superiore di Sanità, Roma.
出版信息
Blood Transfus. 2010 Jan;8(1):8-16. doi: 10.2450/2009.0108-09.
Abstract
摘要
相似文献
1
The role of antenatal immunoprophylaxis in the prevention of maternal-foetal anti-Rh(D) alloimmunisation.
Blood Transfus. 2010 Jan;8(1):8-16. doi: 10.2450/2009.0108-09.
2
[Foetomaternal erythrocyte incompatibilities: from immunohaematologic surveillance of pregnant women to haemolytic disease of the newborn].
Transfus Clin Biol. 2005 Feb;12(1):45-55. doi: 10.1016/j.tracli.2005.02.001.
3
Prevention of haemolytic disease of the newborn by anti-D serum given to the mother.
Ger Med Mon. 1967 Dec;12(12):570-1.
4
Prevention of Rh haemolytic disease.
Nurs Mirror Midwives J. 1974 Oct 24;139(17):57-9.
5
[Development and present status of immunoprophylaxis of Rh-sensitization].
Z Arztl Fortbild (Jena). 1970 Dec 1;64(3):1181-5.
6
[Foetal erythrocytes in maternal blood and immunoprophylaxis of Rh-immunization. Clinical and experimental studies].
Acta Obstet Gynecol Scand Suppl. 1972;20:1-128.
7
[Prevention of RH-erythroblastosis by anti-D-application to the mother].
Monatsschr Kinderheilkd (1902). 1968 Jun;116(6):236-8.
8
[Prevention of Rh sensitization using immunoglobulin anti-D].
Schweiz Med Wochenschr. 1969 Oct 18;99(42):1519-21.
9
Use of different doses of anti-Rh IgG in the prevention of Rh isoimmunisation.
Lancet. 1969 Aug 9;2(7615):288-90. doi: 10.1016/s0140-6736(69)90053-1.
10
[Immunoprophylaxis in serologic incompatibility].
Pediatr Pol. 1973 Jun;48(6):771-7.
引用本文的文献
1
Patient experience and burden of haemolytic disease of the foetus and newborn: a systematic review.
BMC Pregnancy Childbirth. 2025 Feb 4;25(1):114. doi: 10.1186/s12884-025-07208-9.
2
Red Blood Cell Alloimmunization in Pregnancy: A Review of the Pathophysiology, Prevalence, and Risk Factors.
Cureus. 2024 May 12;16(5):e60158. doi: 10.7759/cureus.60158. eCollection 2024 May.
3
Maternal red blood cell alloimmunization prevalence in the United States.
Blood Adv. 2024 Aug 27;8(16):4311-4319. doi: 10.1182/bloodadvances.2023012241.
4
Noninvasive fetal blood group antigen genotyping.
Blood Transfus. 2025 Mar;23(2):101-108. doi: 10.2450/BloodTransfus.712. Epub 2024 Jan 29.
5
Immunohaematological conundrums in obstetrics from transfusion services viewpoint in Armed Forces setup.
Med J Armed Forces India. 2023 May-Jun;79(3):280-285. doi: 10.1016/j.mjafi.2021.05.017. Epub 2021 Aug 13.
6
Upregulation of miR-181a-5p and miR-125b-2-3p in the Maternal Circulation of Fetuses with Rh-Negative Hemolytic Disease of the Fetus and Newborn Could Be Related to Dysfunction of Placental Function.
Dis Markers. 2022 Sep 21;2022:2594091. doi: 10.1155/2022/2594091. eCollection 2022.
7
Fetal-maternal incompatibility in the Rh system. Rh isoimmunization associated with hereditary spherocytosis: case presentation and review of the literature.
Rom J Morphol Embryol. 2022 Jan-Mar;63(1):229-235. doi: 10.47162/RJME.63.1.26.
8
Recommendation for validation and quality assurance of non-invasive prenatal testing for foetal blood groups and implications for IVD risk classification according to EU regulations.
Vox Sang. 2022 Feb;117(2):157-165. doi: 10.1111/vox.13172. Epub 2021 Jun 21.
9
Educational Case: Anemia in a Neonate.
Acad Pathol. 2021 Apr 8;8:23742895211002829. doi: 10.1177/23742895211002829. eCollection 2021 Jan-Dec.
10
Prevalence of rhesus D-negative blood type and the challenges of rhesus D immunoprophylaxis among obstetric population in Ethiopia: a systematic review and meta-analysis.
Matern Health Neonatol Perinatol. 2021 Feb 2;7(1):8. doi: 10.1186/s40748-021-00129-3.
本文引用的文献
1
Anti-D administration in pregnancy for preventing Rhesus alloimmunisation.
Cochrane Database Syst Rev. 2013 Feb 28(2):CD000020. doi: 10.1002/14651858.CD000020.pub2.
2
Implementation of NICE recommendation for a policy of routine antenatal anti-D prophylaxis: a survey of UK maternity units.
Transfus Med. 2008 Oct;18(5):292-5. doi: 10.1111/j.1365-3148.2008.00882.x.
3
Lessons learnt from many years of experience using anti-D in humans for prevention of RhD immunization and haemolytic disease of the fetus and newborn.
Clin Exp Immunol. 2008 Oct;154(1):1-5. doi: 10.1111/j.1365-2249.2008.03735.x. Epub 2008 Aug 22.
4
The determination of the fetal D status from maternal plasma for decision making on Rh prophylaxis is feasible.
Transfusion. 2008 Nov;48(11):2292-301. doi: 10.1111/j.1537-2995.2008.01843.x. Epub 2008 Aug 7.
5
RHD genotyping from maternal plasma: guidelines and technical challenges.
Methods Mol Biol. 2008;444:185-201. doi: 10.1007/978-1-59745-066-9_14.
6
Integrating molecular technologies for red blood cell typing and compatibility testing into blood centers and transfusion services.
Transfus Med Rev. 2008 Apr;22(2):117-32. doi: 10.1016/j.tmrv.2007.12.002.
7
An increased risk for non allo-immunization related intrauterine fetal death in RhD-negative patients.
J Matern Fetal Neonatal Med. 2008 Apr;21(4):255-9. doi: 10.1080/14767050801928804.
8
New technologies to replace current blood typing reagents.
Curr Opin Hematol. 2007 Nov;14(6):677-81. doi: 10.1097/MOH.0b013e3282ef1838.
9
Efficacy of RhD monoclonal antibodies in clinical trials as replacement therapy for prophylactic anti-D immunoglobulin: more questions than answers.
Vox Sang. 2007 Aug;93(2):99-111. doi: 10.1111/j.1423-0410.2007.00945.x.
10
Blood group genotyping in Germany.
Transfusion. 2007 Jul;47(1 Suppl):47S-53S. doi: 10.1111/j.1537-2995.2007.01310.x.
Zotero 插件